No.25 CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY



FINANCIAL STATEMENT

4th QUARTER 2024

CONTENTS

---000---

			Pages
1 - Balance sheet			1 - 2
2 - Income statement			3
3 - Cash flow statement			4
4 - Notes to the financial statements			5 - 25

B 01 - DN

BALANCE SHEET

As at 31st December 2024

ITEMS	Code	Notes	31st Dec 2024	01st Jan 2024
A. CURRENT ASSETS	100		292.989.521.837	276.258.362.601
I. Cash and cash equivalents	110	5	28.283.162.460	29.373.283.684
1. Cash	111		15.881.615.411	9.110.316.259
2. Cash equivalents	112		12.401.547.049	20.262.967.425
II. Short-term investments	120		38.000.000.000	21.769.777.151
1. Held- to-maturity investments	123	6	38.000.000.000	21.769.777.151
III. Current accounts receivable	130		26.953.495.054	25.776.266.141
1. Short-term trade receivables	131	7.1	41.517.169.521	37.745.259.525
2. Short-term advances to suppliers	132	7.2	1.112.434.887	5.067.493.887
4. Other short-term receivables	136	8.1	6.437.509.409	4.213.782.909
5. Provision for doubtful short-term receivables	137	9	(22.113.618.763)	(21.250.270.180
IV. Inventories	140	10	199.231.781.635	198.175.934.868
1. Inventories	141		201.768.051.752	200.227.756.189
2. Provision for obsolete inventories	149		(2.536.270.117)	(2.051.821.321
V. Other current assets	150		521.082.688	1.163.100.757
1. Short-term prepaid expenses	151		97.400.000	43.500.000
2. Value-added tax deductible	152	16.1	146.265.258	1.119.600.757
3. Tax and other receivables from the State	153	17a	277.417.430	- 1
B. NON-CURRENT ASSETS	200		94.104.163.912	95.955.969.060
I. Long-term receivables	210		3.761.660.200	3.761.660.200
6. Other long-term receivables	216	8.2	3.761.660.200	3.761.660.200
II. Fixed assets	220		19.885.928.823	22.643.575.381
Tangible fixed assets	221	11	19.885.928.823	22.643.575.381
- Cost	222		109.629.094.697	111.989.308.056
- Accumulated depreciation	223		(89.743.165.874)	(89.345.732.675
2. Intangible fixed assets	227	12	- 14	-
- Cost	228		334.130.000	334.130.000
- Accumulated depreciation	229		(334.130.000)	(334.130.000
IV. Long-term assets in progress	240		21.237.108.032	19.155.621.629
1. Construction in progress	242	13	21.237.108.032	19.155.621.629
VI. Other long-term assets	260		49.219.466.857	50.395.111.850
1. Long-term prepaid expenses	261		48.562.134.538	50.186.494.000
2. Deferred tax assets	262		657.332.319	208.617.850
TOTAL ASSETS	270		387.093.685.749	372.214.331.661

B 01 - DN

BALANCE SHEET (continued) As at 31st December 2024

Currency: VND

ITEMS	Code	Notes	31st Dec 2024	01st Jan 2024
C. LIABILITIES	300		231.941.580.577	220.132.539.936
I. Current liabilities	310		230.931.484.623	218.980.933.987
1. Short-term trade payables	311	14	14.081.726.952	2.737.597.363
2. Short-term advances from customers	312	15	183.085.955.477	209.512.299.972
3. Statutory obligations	313	16.2		390.224.339
4. Payables to employees	314		5.088.183.710	3.559.706.767
5. Short-term accrued expenses	315	17	739.841.076	1.183.797.434
6. Other short-term payables	319	18	27.886.071.461	1.485.702.165
9. Bonus and welfare fund	322	19	49.705.947	111.605.947
II. Non-current liabilities	330		1.010.095.954	1.151.605.949
2. Long-term provisions	342	20	959.997.500	1.043.089.250
13. Scientific and technological development fund	343		50.098.454	108.516.699
D. OWNERS' EQUITY	400		155.152.105.172	152.081.791.725
I. Capital	410	21	155.152.105.172	152.081.791.725
1. Share capital	411		132.946.410.000	132.946.410.000
2. Share premium	412		17.589.282.000	17.589.282.000
3. Investment and development fund	418		12.490.339.501	12.490.339.501
4. Accumulated losses	421		(7.873.926.329)	(10.944.239.776
- Accumulated losses by the end of prior year	421a		(10.944.239.776)	(13.155.164.174
- Undistributed earnings	421b		3.070.313.447	2.210.924.398
TOTAL LIABILITIES AND OWNERS' EQUITY	440		387.093.685.749	372.214.331.661

PREPARER CUM CHIEF ACCOUNTANT

Ngo Tan Long

Ho Chi Minh City, 20th January 2025

300468377

cổ phần Dược phẩm TW 25

CÔNG T

Nguyen Manh Hai

B02 a - DN

INCOME STATEMENT

The accounting ends in 31st Dec 2024

			ATH OU	ADTED	Accumulatives fro	Currency: VND om Jan till end of
Items C		Notes	4TH QUARTER		the 4th quarter	
	1		2024	2023	2024	2023
Revenue from sale of goods and rendering of services	01	23	46.682.426.304	40.437.912.157	130.580.736.698	140.425.031.762
2. Deductions	02	24	-	249.963.260	157.457	285.445.730
Net revenue from sale of goods and rendering of services	10		46.682.426.304	40.187.948.897	130.580.579.241	140.139.586.032
4. Cost of goods sold and services rendered	11	25	41.914.569.571	35.067.694.654	113.540.448.882	121.886.661.971
Gross profit from sale of goods and rendering of services	1		4.767.856.733	5.120.254.243	17.040.130.359	18.252.924.061
6. Finance income	21	26	914.052.501	1.017.629.285	2.178.507.752	2.623.221.346
7. Finance expenses	22	27	966.639	3.161.331	30.289.235	21.640.948
In which: Interest expenses	23	-	-	-	-	-
8. Selling expenses	25	29.1	1.233.429.963	1.248.594.137	2.327.329.782	4.099.249.30
9. General and administrative expe	26	29.2	3.755.034.393	4.153.742.439	14.302.022.766	14.422.485.20
10. Operating profit	30		692.478.239	732.385.621	2.558.996.328	2.332.769.947
11. Other income	31	30	64.020.000		64.020.000	81.078
12. Other expenses	32	31		16.500.000	1.417.350	118.741.885
13. Other profit	40		64.020.000	(16.500.000)	62.602.650	(118.660.807
14. Accounting profit before tax	50		756.498.239	715.885.621	2.621.598.978	2.214.109.140
15. Current corporate income tax expense	51	32.1				-
16. Deferred tax expense	52	32.2	(450.001.469)		(448.714.469)	3.184.742
17. Net profit after tax	60		1.206.499.708	715.885.621	3.070.313.447	2.210.924.398

Ho Chi Minh City, 20th January 2025

PREPARER CUM CHIEF ACCOUNTANT

Ngo Tan Long

GENNERAL DIRECTOR Nguyen Manh Hai

B 03 - DN

CASH FLOW STATEMENT

(Indirect Method)

The accounting ends in 31st Dec 2024

Items	Code	From 01st Jan till end 31st Dec 2024	From 01st Jan till end 31st Dec 2023
I. CASH FLOWS FROM OPERATING ACTIVITIES		25 m u 16" n su	1
Profit before tax	01	2.621.598.978	2.214.109.140
2. Adjustments for:			
- Depreciation of tangible fixed assets and investment properties	02	2.699.228.313	3.292.369.171
- Provisions	03	1.347.797.379	107.533.013
 Foreign exchange gains arising from revaluation of monetary accounts denominated in monetary currency 	04	(10.610.533)	(8.439.102)
- (Profits)/losses from investing activities	05	(2.068.408.066)	(2.339.148.195)
3. Operating profit before changes in working capital	08	4.589.606.071	3.266.424.027
- (Increase)/decrease in receivables	09	(1.067.241.997)	1.467.155.141
- (Increase)/decrease in inventories	10	(1.540.295.563)	15.056.311.718
- Increase/(decrease) in payables	11	11.596.241.456	(4.425.723.549)
- (Increase)/decrease in prepaid expenses	12	1.570.459.462	(13.966.354)
- Other cash outflows for operating activities	17	(61.900.000)	(95.800.000)
Net cash flows from operating activities	20	15.086.869.429	15.254.400.983
II. CASH FLOWS FROM INVESTING ACTIVITIES			
1. Purchase and construction of fixed assets and other long-term assets	21	(2.081.486.403)	•
2. Proceeds from disposals of fixed assets and other long-term assets	22	55.700.000	
Loans to other entities and payments for purchase of debt instruments of other entities	23	(65.000.000.000)	(38.170.755.656)
Collections from borrowers and proceeds from sale of debt instruments of 4. other entities	24	48.769.777.151	35.000.000.000
7. Interest and dividends received	27	2.068.408.066	2.339.148.195
Net cash flows from investing activities	30	(16.187.601.186)	(831.607.461)
II.CASH FLOWS FROM FINANCING ACTIVITIES			
5. Dividends paid/Profit distributed	36		(2.566.000)
Net cash flows from financing activities	40		(2.566.000)
Net increase/(decrease) in cash for the year (50 = 20+30+40)	50	(1.100.731.757)	14.420.227.522
Cash and cash equivalents at beginning of year	60	29.373.283.684	14.944.617.060
mpact of exchange rate fluctuation	61	10.610.533	8.439.102
Cash and cash equivalents at end of year (70 = 50+60+61)	70	28.283.162.460	29.373.283.684

Ho Chi Minh City, 20th January 2025

PREPARER CUM CHIEF ACCOUNTANT

Ngo Tan Long

03004665 NNERAL DIRECTOR

Nguyen Manh Hai

B 09 - DN

NOTES TO THE FINANCIAL STATEMENTS

The accounting ends in 31st Dec 2024

1. CORPORATE INFORMATION

Type of Business: Joint Stock Company

No. 25 Central Pharmaceutical Joint Stock Company was was converted from a state-owned enterprise according to Decision No. 5112/QD9-BYT dated 11 December 2006, by the Minister of Health, approving the plan to convert the Company into a joint stock company. The initial business registration certificate No. 0300468511 was issued on 19 June 2007, and the 19th amendment was registered on 6 June 2024, by the Department of Planning and Investment of Ho Chi Minh City.

Business Areas: Manufacturing, Services

Business Activities: Manufacturing and trading pharmaceuticals, manufacturing and selling cosmetics. Producing non-alcoholic beverages, mineral water (not produced at the headquarters). Trading in soft drinks (no food and beverage services at the headquarters). Manufacturing and selling paper and plastic packaging (no waste recycling at the headquarters). Manufacturing medical equipment and instruments (not produced at the headquarters). Trading in medical machinery and equipment. Manufacturing and selling chemical cosmetics (not produced at the headquarters). Real estate business

Tourism Accommodation Business: Hotels (not operated at the headquarters). Guesthouses, inns providing short-term lodging services (not operated in Ho Chi Minh City

Bán lẻ máy ảnh, phim ảnh, thiết bị quang học và thiết bị chính xác; bán lẻ tranh, tượng,.../ Retail of cameras, films, optical equipment, and precision instruments; retail of paintings, statues

Manufactoring flour-based confectionery. Milling and production of raw flour. Production of cocoa, chocolate and confectionery. Manufactoring other foods not elsewhere classified (details: production of special foods such as production of functional foods, nutritional foods, milk and other foods

The Company's shares coding UPH were listed on the Hanoi Stock Exchange in accordance with the Decision No. 856/QĐ-SGDHN issued by the Hanoi Stock Exchange on 19 December 2016.

The Company's head office is located at 448B Nguyen Tat Thanh, Ward 18, District 4, Ho Chi Minh City, Vietnam

Normal Business Cycle

The Company's normal business cycle is conducted within a period not exceeding 12 months

2. ACCOUNTING PERIOD, CURRENCY UNIT USED IN ACCOUNTING

Fiscal year

The Company's fiscal year applicable for the preparation of its financial statements starts on 1 January and ends on 31 December.

Accounting currency

The consolidated financial statements are prepared in VND which is also the Company's accounting currency.

3. ACCOUTING STANDARDS AND SYSTE

Accounting standards

ended 31st December 2024

The Company has applied the Corporate Accounting Regime according to Circular No. 200/2014/TT-BTC issued by the Minister of Finance on 22 December 2014 ("Circular 200"). Circular 200 is effective for financial years beginning on or after 1 January 2015 and replaces the Corporate Accounting Regime issued under Decision No. 15/2006/QĐ-BTC dated March 20, 2006, by the Minister of Finance and Circular No. 244/2009/TT-BTC dated 31 December 2009, by the Ministry of Finance, the Vietnamese Accounting Standards issued by the Ministry of Finance, and the accompanying amendments, supplements, and implementation guidelines.

Application of New Accounting Guidelines

On 21 March 2016, the Ministry of Finance issued Circular No. 53/2016/TT-BTC ("Circular 53") amending and supplementing certain provisions of Circular No. 200/2014/TT-BTC dated 22 December 2014, by the Ministry of Finance, which provides guidance on the corporate accounting regime. Circular 53 is effective for financial years beginning on or after 1 January 2016. The Company has applied Circular 53 in the preparation and presentation of its separate financial statements for the financial year ended 31 December 2016

Statement of Compliance with Accounting Standards and Accounting System

The Company has applied the Vietnamese Accounting Standards and the guiding documents issued by the Ministry of Finance. The financial statements are prepared and presented in accordance with all the provisions of each standard, the implementation guidance circulars, and the current applicable Accounting System.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied by the Company in preparing the Financial Statements are as follows:

Accounting estimates

The preparation of separate financial statements in compliance with Vietnamese Accounting Standards, the Vietnamese accounting system, and other current accounting regulations in Vietnam requires the Board of Directors to make estimates and assumptions that affect the reported amounts of liabilities, assets, and the disclosure of contingent liabilities and assets at the date of the separate financial statements, as well as the reported amounts of revenue and expenses during the financial year. Although these accounting estimates are made based on the best knowledge of the Board of Directors, actual results may differ from those estimates and assumptions.

Financial instruments

Initial Recognition

Financial Assets: At initial recognition, financial assets are recorded at cost plus any directly attributable transaction costs related to the acquisition of the financial asset. The Company's financial assets include cash and cash equivalents, short-term financial investments, trade receivables, other receivables, short-term loans receivable, and deposits..

Financial Liabilities: At initial recognition, financial liabilities are recorded at cost plus any directly attributable transaction costs related to the issuance of the financial liability. The Company's financial liabilities include trade payables and other payables, accrued expenses, and loans...

Re-evaluate after initial recognition

Currently, there are no regulations regarding the revaluation of financial instruments after initial recognition

Cash and Cash equivalents

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of not more than than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of change in value.

Financial investments

Held-for-trading securities

Held-for-trading securities are securities held by the Company for trading purposes. Held-for-trading securities are recorded from the date the Company acquires ownership and are initially measured at the fair value of the payments at the time the transaction occurs add costs related to the purchase of held-for-trading securities

In subsequent accounting periods, securities investments are determined at original cost minus any reduction in the value of trading securities.

Provision for impairment of held-for-trading securities is made in accordance with current accounting regulations

Loan receivables

Loans are measured at cost less any provision for doubtful debts. Provisions for doubtful debts on the Company's loans are made in accordance with current accounting regulations

Investment in subsidiary

Subsidiaries are companies controlled by the Company. Control is achieved when the Company has the ability to govern the financial and operating policies of the investee companies to obtain benefits from their operations.

Joint venture capital contribution

Joint venture capital contributions are agreements made by contract whereby the Company and the participating parties engage in economic activities based on joint control. Joint control means that strategic decisions regarding the operating and financial policies of the joint venture entity require the unanimous consent of the parties sharing control.

Investment in Associates

An associate is a company over which the Company has significant influence but is neither a subsidiary nor a joint venture of the Company. Significant influence is the power to participate in the financial and operating policy decisions of the investee but does not entail control or joint control over those policies.

Investment in Other Entities

Investment in other entities reflects investments where the company does not have control, joint control, or significant influence over the investee. Investments in equity instruments of other entities are recorded at original cost less any provision for impairment.

Provisions for impairment of investments in other entities are made in accordance with current accounting regulations.

Financial investments (continued)

The company initially recognizes investments in subsidiaries, joint ventures, and associates at cost. The company records in the income statement the share of cumulative net profit of the investee arising after the investment date. Any amounts received by the company other than the share of profit are considered a recovery of the investment and are recorded as a reduction in the original cost of the investment.

Investments in subsidiaries, joint ventures, and associates are presented in the balance sheet at cost less any provision for impairment (if any).

Receivables

Receivables are amounts recoverable from customers or other parties. Receivables are presented at their carrying value less any provision for doubtful debts.

Provisions for doubtful debts are made for receivables that are overdue for six months or more, or for receivables where the debtor is unlikely to pay due to liquidation, bankruptcy, or similar difficulties.

Inventory

Inventory is valued at the lower of cost and net realizable value. The cost of inventory includes purchase costs, direct material costs, direct labor costs, and, if applicable, manufacturing overheads to bring the inventory to its current location and condition. The cost of inventory is determined using the specific identification method. Net realizable value is the estimated selling price less the costs of completion and selling expenses.

Provisions for inventory devaluation are made in accordance with current accounting regulations. Accordingly, the Company is allowed to make provisions for obsolete, damaged, or substandard inventory and in cases where the carrying amount of inventory exceeds its net realizable value at the end of the financial year.

Fixed Assets

Tangible Fixed Assets and Depreciation

Tangible fixed assets are presented at cost less accumulated depreciation.

The cost of tangible fixed assets includes the purchase price and all other direct costs related to bringing the asset to its working condition for its intended use.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives, as follows:

Buildings and structures	05 - 45 years
Machinery and equipment	03 - 10 years
Means of transportation	03 - 10 years
Office equipment	03 - 08 years

Intangible Fixed Assets and Amortization

Intangible fixed assets include the value of land use rights with definite and indefinite terms and computer software, which are presented at cost less accumulated amortization.

Indefinite-term land use rights are not amortized according to current regulations. Definite-term land use rights are amortized using the straight-line method over the land use period. Computer software is amortized using the straight-line method over a period of five years

Deferred Corporate Income Tax

Deferred income tax is calculated on the differences between the carrying amounts of assets or liabilities on the balance sheet and their tax bases. Deferred income tax is accounted for using the balance sheet method. Deferred income tax liabilities are recognized for all taxable temporary differences, while deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized

ended 31st December 2024

Deferred income tax is determined using tax rates that are expected to apply in the period when the asset is realized or the liability is settled. Deferred income tax is recognized in the income statement, except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Deferred income tax assets and deferred income tax liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis

Prepaid Expenses

Prepaid expenses include actual costs incurred that relate to the business operations of multiple accounting periods. Prepaid expenses include prepaid land rent, rental fees for premises, and other prepaid expenses.

Prepaid land rent represents the amount of land rent paid in advance. Prepaid land rent is allocated to the income statement on a straight-line basis over the lease term.

Other prepaid expenses include costs related to the company's production activities. These costs are capitalized as prepaid expenses and allocated to the income statement using the straight-line method in accordance with current accounting regulations

Borrowing Costs

Borrowing costs are recognized as an expense in the year in which they are incurred, except when they are capitalized in accordance with Vietnamese Accounting Standard No. 16 'Borrowing Costs'.

Accrued Expenses

Accrued expenses are recognized when actual costs have not yet been paid but have been anticipated and included in the production and business expenses for the period to ensure that when the actual costs are incurred, they do not cause sudden spikes in production and business expenses, thereby ensuring the matching principle between revenue and expenses. When these costs are incurred, if there is a difference from the amount accrued, the accounting will record an additional expense or reduce the expense corresponding to the difference.

Provisions

Provisions are recognized when the Company has a present obligation as a result of a past event, and it is probable that the Company will be required to settle that obligation. Provisions are determined based on the estimates of the Board of Directors regarding the necessary costs to settle the obligation at the end of the financial year.

Severance Payable

Severance payable for employees is accrued for all employees who have worked at the Company for more than 12 months up to December 31, 2008. The accrual for each year of service up to December 31, 2008, is equal to half of the average monthly salary in accordance with the Labor Law, the Social Insurance Law, and related guiding documents. Any increase or decrease in this accrual will be recognized in the income statement.

Equity

Owner's Investment: Recognized based on the actual capital contributed by the owner and the capital supplemented from after-tax profits during the operation.

Share Premium: Recognized based on the excess amount between the actual issuance price and the par value of shares in joint-stock companies when shares are initially issued and when additional shares are issued.

Retained Earnings: The after-tax profits not yet distributed, as reflected on the balance sheet, represent the profits from the company's operations after deducting corporate income tax, dividends, reserves, and funds appropriated from after-tax profits

Revenue Recognition

Sales revenue is recognized when all of the following five conditions are satisfied:

- The Company has transferred the significant risks and rewards of ownership of the goods to the buyer;
- The Company no longer retains control over the goods sold as an owner or control over the goods;
- The revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the Company; and
- The costs incurred or to be incurred in respect of the transaction can be measured reliably.

 Revenue from service transactions is recognized when the outcome of the transaction can be measured reliably. If the service transaction spans multiple periods, revenue is recognized in the period based on the stage of completion of the transaction at the end of the accounting period. The outcome of a service transaction is determined when all of the following four conditions are satisfied
 - The revenue can be measured reliably;
 - It is probable that the economic benefits associated with the service transaction will flow to the Company;
 - The stage of completion of the transaction at the end of the accounting period can be measured reliably; and
 - The costs incurred for the transaction and the costs to complete the service transaction can be measured reliably.

Interest income is recognized on an accrual basis, determined based on the balance of deposit accounts and the applicable interest rates. Income from investments is recognized when the Company has the right to receive the interest.

Foreign Currency

Transactions arising in foreign currencies are translated at the exchange rates on the transaction dates. Monetary items denominated in foreign currencies at the end of the financial year are translated at the exchange rates on that date. Exchange differences arising are recognized in the income statement. Exchange gains resulting from the revaluation of balances at the end of the accounting period are not distributed to shareholders

Corporate Income Tax

Corporate income tax represents the total value of current tax liabilities and deferred tax.

Current tax liabilities are calculated based on taxable income for the year. Taxable income differs from the net profit reported in the income statement because it excludes taxable income or deductible expenses in other years (including carryforward losses, if any) and also excludes non-taxable income and non-deductible expenses

The determination of the Company's payable corporate income tax and deferred tax is based on the current tax regulations. However, these regulations change over time, and the final determination of corporate income tax depends on the results of examinations by the competent tax authorities.

The corporate income tax rate for 2024 is 20%.

Related Parties

Related parties are entities, including parent companies and subsidiaries, and individuals, directly or indirectly through one or more intermediaries, that have control over the company, are controlled by the company, or are under common control with the company. Related parties also include associates, individuals who directly or indirectly hold voting rights in the company and have significant influence over the company, key management personnel of the company, close family members of these individuals or associates, and entities associated with these individuals.

In considering the relationship of each related party, the substance of the relationship is taken into account rather than merely the legal form

5. CASH AND CASH EQUIVALENTS	31st Dec 2024 VND	01st Jan 2024 VND
- Cash	72.000.507	317.936.444
- Cash in banks	15.809.614.904	8.792.379.815
- Cash equivalents	12.401.547.049	20.262.967.425
	28.283.162.460	29.373.283.684
6. SHORT-TERM INVESTMENTS	31st Dec 2024 VND	01st Jan 2024 VND
-Held- to-maturity investments	38.000.000.000	21.769.777.151
+ 6-months term deposits	38.000.000.000	21.769.777.151
	38.000.000.000	21.769.777.151
7. SHORT - TERM TRADE RECEIVABLES AND ADVANCES TO SUPPLIERS		
7.1 Short-term trade receivables	31st Dec 2024 VND	01st Jan 2024 VND
- OPC Pharmaceutical Joint Stock Company (related parties)	16.956.659.585	16.419.454.616
- Kim Long Business and Contruction Company Limited	12.825.176.072	12.825.176.072
- Other customers	11.735.333.864	8.500.628.837
	41.517.169.521	37.745.259.525
7.0.06	04-4 D 0004	04-4 1 0004
7.2 Short-term advances to suppliers	31st Dec 2024 VND	01st Jan 2024 VND
- Misa Joint Stock Company	VIND	141.695.000
- Sagen Constructive Design Consultancy Joint Stock Company	254.260.000	254.260.000
- Dung Phat Trading Development Investment Company Limited	431.200.000	431.200.000
- Ningxia Qiyuan Pharma		3.567.726.000
- Branch of Ky Bac Exact Mechanic Joint Stock Company	107.250.000	-
- Other suppliers	319.724.887	672.612.887
	1.112.434.887	5.067.493.887

No.25 CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4 Ho Chi Minh City, Viet Nam FINANCAL STATEMENT
For the financial year
ended 31st December 2024

8. OTHER RECEIVABLES 31st Dec 2024 01st Jan 2024 VND VND 8.1 Other short-term receivables - Advance payment to employees 120.124.000 84.580.314 - Other Receivables 6.317.385.409 4.129.202.595 + Kim Long Business and Contruction Company Limited 3.601.800.798 3.601.800.798 + Tan Hiep Loi Plastic Packaging Joint Stock 1.995.664.090 + Other receivables 719.920.521 527.401.797 6.437.509.409 4.213.782.909 8.2. Other long-term receivables - Bet; Deposits 125.563.600 125.563.600 - Business cooperation receivables 3.636.096.600 3.636.096.600 from Kim Long Business and Contruction Company Limited 3.761.660.200 3.761.660.200 Provision for doubtful other receivables (3.644.234.494)(3.601.800.798)Net realizable value 6.554.935.115 4.373.642.311 9. BAD DEBTS **Ending Balance** Recoverable Debtor Cost amount VND VND VND - Kim Long Business and Contruction Company Limited 16.426.976.870 (16.426.976.870) - Other partier 5.686.641.893 (5.686.641.893)22.113.618.763 (22.113.618.763) Beginning balance Recoverable Debtor Cost amount VND VND VND - Kim Long Business and Contruction Company Limited 16.426.976.870 (16.426.976.870) - Other partier 4.823.293.310 (4.823.293.310)21.250.270.180 (21.250.270.180) This bad debt has been provisioned by the Company in accordance with current regulations. 10. INVENTORIES 31st Dec 2024 01st Jan 2024 VND VND - Raw materials 29.512.724.979 26.903.004.876 - Real estate for sale 160.622.501.912 160.622.501.912 - Tools and supplies 22.024.800 - Work in process 1.640.958.292 1.903.501.858 - Finished goods 9.958.599.769 10.785.275.543 - Merchandise 11.242.000 13.472.000 - Provision for obsolete inventories (2.536.270.117)(2.051.821.321)199.231.781.635 198.175.934.868

11. INCREASE/DECREASE TANGIBLE FIXED ASSETS

Items	Buildings and structures	Machinery and equipment	Means of transportation	Office equipment	Total
	VND	VND	VND	VND	VND
COST					
At 01st Jan 2024	38.973.526.498	69.540.110.815	2.713.306.813	762.363.930	111.989.308.056
New purchase	- 1	-	-		
Disposal	s=	(2.360.213.359)	12		- 2.360.213.359
At 31st Dec 2024	38.973.526.498	67.179.897.456	2.713.306.813	762.363.930	109.629.094.697
ACCUMULATED DEP	RECIATION				
At 01st Jan 2024	22.916.293.602	63.151.224.150	2.516.897.514	761.317.409	89.345.732.675
Depreciation for the year	871.321.552	1.795.036.925	90.241.560	1.046.521	2.757.646.558
Disposal	_	(2.360.213.359)	: M.		- 2.360.213.359
At 31st Dec 2024	23.787.615.154	62.586.047.716	2.607.139.074	762.363.930	89.743.165.874
NET CARRYING AMO	UNT	A 2 1 = 1			
At 01st Jan 2024	16.057.232.896	6.388.886.665	196.409.299	1.046.521	22.643.575.381
At 31st Dec 2024	15.185.911.344	4.593.849.740	106.167.739		19.885.928.823
In which: Original price		-			
	4.513.091.128	54.871.901.441	2.081.615.904	762.363.930	62.228.972.403
12. INCREASE/DECRI	EASE INTANGIBLE	FIXED ASSETS			
			Computer	Other intagible	Total
Items			software	fixed assets	
			VND		VND
COST					160
At 01st Jan 2024		_	250.230.000	83.900.000	334.130.000
At 31st Dec 2024			250.230.000	83.900.000	334.130.000
ACCUMULATED DEP	RECIATION				
At 01st Jan 2024			250.230.000	83.900.000	334.130.000
Depreciation for the year	ar				-
At 31st Dec 2024		- <u>-</u>	250.230.000	83.900.000	334.130.000
NET CARRYING AMO	UNT				
At 01st Jan 2024			·		
At 31st Dec 2024					-
In which: Original price	of assets has been	fully depreciated but	is still in use		
			250.230.000	83.900.000	334.130.000

No.25 CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY
Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4
Ho Chi Minh City, Viet Nam

13. CONTRUCTION IN PROGRESS	31st Dec 2024 VND	01st Jan 2024 VND
- Construction in progress at Tan Phu Trung industrial park	21.237.108.032	19.155.621.629
	21.237.108.032	19.155.621.629
14. SHORT-TERM TRADE PAYABLES	31st Dec 2024 VND	01st Jan 2024 VND
Trade payables	14.035.264.452	2.688.247.363
- Tan Thanh packaging Company Limited	1.000.090.487	361.764.818
- Benovas Pharmaceutical Joint Stock Company	1.813.699.620	991 525 428
- Viet Uy Trading Joint Stock Company	1.921.500.000	
- Phuong Phuc Pharmaceutical Chemical Company Limited	1.600.630.668	91.323.750
- Sinobright Pharmaceutical Co.,ltd.	4.225.113.360	-
- Other suppliers	3.474.230.317	1.243.633.367
Trade payables to related parties	46.462.500	49.350.000
- OPC - Binh Duong Pharmaceutical only member Co., Ltd (R	telated partiers) 46.462.500	49,350,000
	14.081.726.952	2.737.597.363

All short-term trade payables are expected to be settled on 1st January 2024, and 31st December 2024.

15. ADVANCES FROM CUSTOMERS	31st Dec 2024 VND	01st Jan 2024 VND
- Tay Ninh Industrial Park Infrastructure development Joint Stock Company	178.082.838.961	178.082.838.961
- Southern Public Interest Environmental Corporation	-	26.250.000.000
- An Phat Business Investment Trading Joint Stock Company	5.000.000.000	5.000.000.000
- Other customers	3.116.516	179.461.011
	183.085.955.477	209.512.299.972

16. TAX AND OTHER RECEIVALBLES/PAYABLES FROM THE STATE

16.1. Tax receivalbles from the States	01st Jan 2024 VND	Receivable for the year VND	Payment received in the year VND	31st Dec 2024 VND
- Value added tax	1.119.600.757	5.896.620.874	6.661.396.073	354.825.558
- Personal income tax		68.857.130		68.857.130
	1.119.600.757	5.965.478.004	6.661.396.073	423.682.688

16.2. Payables	01st Jan 2024 VND	Payable for the year VND	Payment made in the year VND	31st Dec 2024 VND
- Value added tax		9.092.722.964	9.092.722.964	
- Personal income tax	390.224.339	1.056.761.925	1.446.986.264	
- Land rent		13.843.782.797	13.843.782.797	
- Other taxes		68.071.391	68.071.391	
	390.224.339	24.061.339.077	24.451.563.416	(
17. SHORT-TERM ACCRUED EXPENSES			31st Dec 2024 VND	01st Jan 2024 VND
- Commission for selling				200.376.434
- Other Short-term accrued expenses			739.841.076	983.421.000
		_	739.841.076	1.183.797.434
18.OTHER SHORT-TERM PAYABLES			31st Dec 2024 VND	01st Jan 2024 VND
- Deposits received			420.000.000	420.000.000
- Trade union fee			225.233.841	220.118.044
- Dividends			221.634.744	221.444.934
- Southern Public Interest Environmental C	orporation		26.500.000.000	
- Other payables			519.202.876	624.139.187
		=	27.886.071.461	1.485.702.165
19. BONUS AND WELFARE FUND			Current year VND	Previous year VND
- Beginning balance			111.605.947	207.405.947
- Use fund			(61.900.000)	(95.800.000)
- Ending balance			49.705.947	111.605.947
20. LONG-TERM PROVISIONS			31st Dec 2024 VND	01st Jan 2024 VND
- Severance payable for employees			959.997.500	1.043.089.250

21. OWNERS' EQUITY

a) Increase and decrease in owners' equity

Items	Share capital	Share premium	Investment and development fund	Undistributed earnings	Total
PREVIOUS YEAR					
I. Beginning balance	132.946.410.000	17.589.282.000	12.490.339.501	(13.155.164.174)	149.870.867.327
Net profit for the year	\$1.2			2.242.024.020	
II. Ending Balance	132.946.410.000	17.589.282.000	12.490.339.501	2.210.924.398 (10.944.239.776)	2.210.924.398 152.081.791.725
CURRENT YEAR	- 1 3 m				
Net profit for the year		<u>.</u>		3.070.313.447	3.070.313.447
III. Ending Blance at 31st December 2024	132.946.410.000	17.589.282.000	12.490.339.501	(7.873.926.329)	155.152.105.172
b) Contributed Share Capital					
		31st Dec 2024	% of ownership	01st Jan 2024	% of ownership
Contributed by OPC Pharmaceutical Joint Sto	ck Company	77.300.000.000	58,14%	77.300.000.000	58,14%
Contributed by Vietnam Pharmaceutical Corpo	oration - JSC	37.800.000.000	28,43%	37.800.000.000	
Other Owner's Equity		17.846.410.000	According to the second	17.846.410.000	28,43%
Total		132.946.410.000	13,42% 100%	132.946.410.000	13,42% 100%

21. OWNERS' EQUITY (continued) **Detail of Shares capital** 31st Dec 2024 01st Jan 2024 VND VND - Beginning balance 132.946.410.000 132.946.410.000 - Increase shares capital - Ending balance 132.946.410.000 132.946.410.000 **Shares** 31st Dec 2024 01st Jan 2024 Number of shares registered and issued (Shares): 13.294.641 13.294.641 Number of outstanding shares (Shares) 13.294.641 13.294.641 Par value of shares (VND) 10.000 10.000

The Company has only one type of common share with a par value of 10,000 VND per share. Shareholders holding common shares are entitled to receive dividends when declared and have the right to vote at the Company's shareholder meetings, with one vote per share owned. All shares have equal rights to the net assets of the Company.

Dividends	Current year VND	Previous year VND
- Beginning Balance	221.444.934	224.010.934
- Dividends declared and provisionally appropriated during the year	189.810	-
- Dividends paid during the year	-	(2.566.000)
- Ending Balance	221.634.744	221.444.934
22. OFF-BALANCE SHEET ITEMS		
Foreign Currency	31st Dec 2024	01st Jan 2024
- United States Dollars ("USD")	387,45	618,35
23. REVENUE FROM SALE OF GOODS AND RENDERING OF SERVICES	From 01st Jan till end 31st Dec 2024	From 01st Jan till end 31st Dec 2023
	VND	VND
- Revenue from sales of finished goods and merchandise	127.932.370.754	138.340.695.060
- Revenue from sale of raw materials	533.059.521	54.902.770
- Rendering of services	2.115.306.423	2.029.433.932
	130.580.736.698	140.425.031.762
24. DEDUCTIONS	From 01st Jan till	From 01st Jan till
	end 31st Dec 2024	end 31st Dec 2023
	VND	VND
- Sales returns	157.457	285.445.730
	157.457	285.445.730

; E E Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4 Ho Chi Minh City, Viet Nam FINANCAL STATEMENT For the financial year ended 31st December 2024

25. COST OF GOODS SOLD AND SERVICES RENDERED	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Cost of finished goods and merchandise sold	111.874.571.994	120.690.742.835
- Cost of raw materials sold	519.724.920	46.330.800
- Cost of services rendered	1.146.151.968	1.149.588.336
	113.540.448.882	121.886.661.971
26. FINANCE INCOME	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Interest income	2.068.408.066	2.339.148.195
- Foreign exchange gains	110.099.686	284.073.151
	2.178.507.752	2.623.221.346
27. FINANCE EXPENSES	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Foreign exchange losses	30.289.235	21.640.948
	30.289.235	21.640.948
28. PRODUCTION AND BUSINESS EXPENSES PER FACTOR	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
	04 400 004 057	20 220 010 200
- Raw material costs	84.492.901.057	88.339.918.296
- Labour costs	23.388.317.719	26.038.643.915
- Depreciation costs	2.699.228.313	3.292.369.171 2.187.160.577
- Commission costs	240.004.004	
- Professional service fees	243.684.881	5.601.733.179
- Other expenses	15.590.667.977 126.414.799.947	10.902.792.071 136.362.617.209
	120.414.733.347	100.002.017.200
29. SELLING EXPENSES AND GENERAL AND ADMINISTRATIVE EXPENSE	ES	
29.1. Selling expenses	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Labour costs	1.178.764.934	1.440.744.224
- Commission costs	-	2.187.160.577
- Raw material, Tools and supplies costs	50.092.125	
- Depreciation of tangible fixed assets	50.436.360	-
- Chi phí dịch vụ mua ngoài/ Professional service fees	17.928.000	-
		474 244 500
- Chi phi bán hàng khác/ Other selling expenses	1.030.108.363	471.344.506

Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4

Ho Chi Minh City, Viet Nam

FINANCAL STATEMENT For the financial year ended 31st December 2024

		A contract of the contract of
29.2. General and administrative expenses	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Labour costs	6.858.767.449	7.396.763.330
- Raw material, Tools and supplies costs	254.211.819	-
- Depreciation of tangible fixed assets	89.370.521	100.880.484
- Taxes, fees	139.166.907	-
- Professional service fees	320.842.000	3.893.634.307
- Other expenses	6.639.664.070	3.031.207.084
	14.302.022.766	14.422.485.205
30. OTHER INCOME	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Other income	64.020.000	81.078
	64.020.000	81.078
31. OTHER EXPENSES	From 01st Jan till end 31st Dec 2024 VND	end 31st Dec 2023
	1.417.350	118.741.885
- Other expenses	1.417.350	
		

32. THE CORPORATE INCOME TAX

The corporate income tax ("CIT") rate applicable to the Company is 20% on taxable income.

The tax reports of the Company and its subsidiaries are subject to examination by the tax authorities. As the application of tax laws and regulations to various transactions can be interpreted differently, the tax amounts presented in the consolidated financial statements for the financial year ended December 31, 2024, may be subject to change based on the final decision of the tax authorities. The tax authorities have examined the Company's corporate income tax up to the end of 2021.

32.1 Corporate income tax expense

Current corporate income tax expense	months period ends	months period ends in 31st Dec 2023
	VND	VND
Current corporate income tax (CIT) expense Deferred corporate income tax (CIT) expense Total	(448.714.469) (448.714.469)	3.184.742 3.184.742

The accounting 12

No.25 CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4 Ho Chi Minh City, Viet Nam FINANCAL STATEMENT
For the financial year
ended 31st December 2024

The following is a reconciliation of corporate income tax (CIT) expense and the result of total accounting profit before tax multiplied by the CIT rate:

	The accounting 12 months period ends in 31st Dec 2024	The accounting 12 months period ends in 31st Dec 2023
	VND	VND
Accounting profit before tax	2.621.598.978	2.214.109.140
The corporate income tax rate for 2024 is 20%.	524.319.796	442.821.828
Adjustments for:		
Non-deductible expenses	223.540.778	437.056.683
Adjustment for under-provision of CIT in previous years	-	58.774.800
CIT expense calculated on taxable income for the current year	747.860.573	938.653.311
Offset by prior year losses carried forward	(731.242.223)	(935.468.569)
Deferred CIT expense	16.618.350	3.184.742
Current CIT expense		

32.2 Deferred tax expense

The Company has recognized certain deferred corporate income tax assets with movements during the reporting year and the previous year as follows

	Balance Sheet		Income statement	
	Ending balance	Beginning balance	Current year	Previour year
Severance Payable	191,999.500	208.617.850	16.618.350	3.184.742
Deferred tax expense	465.332.819	-	(465.332.819)	-
Total	657.332.319	208.617.850	(448.714.469)	3.184.742

Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4 Ho Chi Minh City, Viet Nam

For the financial year ended 31st December 2024

33. FINANCIAL INSTRUMENTS

Capital Risk Management

The Company manages its capital to ensure that it can continue as a going concern while maximizing the benefits to shareholders through the optimization of the balance of capital and debt.

The Company's capital structure includes net debt (comprising loans less cash and cash equivalents) and equity attributable to shareholders (including owner's contributed capital, share premium, development investment fund, and retained earnings).

Significant Accounting Policies

Details of the significant accounting policies and methods adopted by the Company (including the criteria for recognition, the basis of measurement, and the basis for recognizing income and expenses) for each class of financial assets and financial liabilities are presented in Note 4.

Types of Financial instruments	31st Dec 2024 VND	01st Jan 2024 VND
Financial Assets - Cash and cash equivalents	28.283.162.460	29.373.283.684
- Trade receivables and other receivables	25.720.936.167 125.563.600	20.624.191.940
- Deposits	92.129.662.227	71.892.816.375
Financial Liabilities	_	-
LoansTrade payables and other payablesAccrued expenses	14.822.564.572 739.841.076	3.583.181.484 1.183.797.434
The state of the s	15.562.405.648	4.766.978.918

Financial Risk Management Objectives

The Company has established a risk management system to identify and assess the risks faced by the Company, and to set policies and procedures to control risks at acceptable levels. The risk management system is reviewed periodically to reflect changes in market conditions and the Company's operations.

Financial risks include market risk (comprising currency risk, interest rate risk, and commodity and equity price risk), credit risk, and liquidity risk.

Market Risk

The Company does not undertake hedging measures for this risk after the Board of Directors assessed that the cost of hedging currency risk or interest rate risk may be higher than the market risk due to future changes in the exchange rates of these financial instruments.

No.25 CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4 Ho Chi Minh City, Viet Nam FINANCAL STATEMENT
For the financial year
ended 31st December 2024

Currency Risk Management

The carrying amounts of monetary assets and liabilities denominated in foreign currencies at the end of the period/year are as follows:

	Asset	Asset		es
	31st Dec 2024 VND	01st Jan 2024 VND	31st Dec 2024 VND	01st Jan 2024 VND
- USD	8.621.149	14.889.868	4.225.113.360	-

Sensitivity Analysis for Foreign Currency

The Company is primarily affected by changes in the exchange rate of the US Dollar. The foreign currency sensitivity analysis applies only to the balances of monetary items denominated in foreign currencies at the end of the period and adjusts the revaluation of these items for a 5% change in the exchange rate. As of 31st December 2024, the Board of Directors used a 5% change rate to analyze currency risk. If the exchange rate of the US Dollar against the Vietnamese Dong increases/decreases by 5%, the Company's profit before tax for the period would be higher/lower by approximately VND 210,824,611. (As of 1st January 2024: VND 744,493).

Interest Rate Risk Management

The Company is exposed to significant interest rate risk arising from interest-bearing loans. The Company is exposed to interest rate risk when it borrows at both floating and fixed interest rates. This risk is managed by the Company by maintaining a reasonable balance between fixed-rate and floating-rate borrowings.

Interest Rate Sensitivity

The sensitivity of borrowings to reasonably possible changes in interest rates is analyzed. Assuming all other variables remain constant, if the interest rates on floating-rate borrowings increase/decrease by 200 basis points, the Company's profit before tax for the financial year ending December 31, 2024, would decrease/increase by 0 VND (as of January 1, 2024; 0 VND). However, the actual borrowings of the Company remain stable according to each debt acknowledgment agreement.

Commodity Price Risk Management

The Company purchases raw materials and goods from both domestic and international suppliers to support its production and business activities. Therefore, the Company is exposed to the risk of changes in the prices of raw materials and goods. This risk is managed by the Company through the seasonal purchasing and stocking of key raw materials.

Equity Price Risk Management

The shares held by the Company are subject to market risks arising from the uncertainty about the future value of the invested shares. The Company manages equity price risk by setting investment limits. The Company's Board of Directors also reviews and approves investment decisions in shares, such as the business sector, companies to invest in, etc. The Company assesses the equity price risk as insignificant.

Credit Risk

Credit risk arises when a customer or counterparty fails to meet their contractual obligations, leading to financial losses for the Company. The Company has an appropriate credit policy and regularly monitors the situation to assess whether it is exposed to credit risk. The Company does not have any significant credit risk with any customers or counterparties as the receivables are from a large number of customers distributed across different geographical areas.

Liquidity Risk Management

The purpose of liquidity risk management is to ensure sufficient capital to meet current and future financial obligations. Liquidity is also managed by the Company to ensure an excess margin between maturing liabilities and maturing assets within a controllable level based on the capital the Company believes it can generate during the period. The Company's policy is to regularly monitor current and forecasted liquidity requirements to ensure that the Company maintains adequate cash reserves, borrowings, and committed shareholder capital to meet short-term and long-term liquidity requirements.

The tables below detail the remaining contractual maturities of non-derivative financial assets and financial liabilities and their repayment terms as agreed. These tables are presented based on the undiscounted cash flows of financial assets and financial liabilities at the earliest date the Company may be required to pay. The presentation of non-derivative financial asset information is necessary to understand the Company's liquidity risk management, as liquidity is managed on a net liability and asset basis.

At 31 December 2024

Financial Assets	Less than 1 year	From 1 to 5 years	Total
	VND	VND	VND
- Cash and cash equivalents	28.283.162.460	-	28.283.162.460
- Short-term investments	38.000.000,000	S=	38.000.000.000
- Trade receivables and other receivables	25.720.936.167		25.720.936.167
- Deposits		125.563.600	125.563.600
	92.004.098.627	125.563.600	92.129.662.227
Financial Liabilities			
- Loans	T#		-
- Trade payables and other payables	14.822.564.572	, =	14.822.564.572
- Accrued expenses	739.841.076		739.841.076
	15.562.405.648		15.562.405.648
Net liquidity spread	76.441.692.979	125.563.600	76.567.256.579

No.25 CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4 Ho Chi Minh City, Viet Nam

For the financial year ended 31st December 2024

At 01 January 2024			
Financial Assets	Less than 1 year VND	From 1 to 5 years VND	Total VND
- Cash and cash equivalents	29.373.283.684		29.373.283.684
- Trade receivables and other receivables	20.624.191.940	-	20.624.191.940
- Deposits		125.563.600	125.563.600
	71.767.252.775	125.563.600	71.892.816.375
Financial Liabilities			
- Loans	(*)	-	-
- Trade payables and other payables	3.583.181.484		3.583.181.484
- Accrued expenses	1.183.797.434	*	1.183.797.434
	4.766.978.918		4.766.978.918
Net liquidity spread	67.000.273.857	125.563.600	67.125.837.457

The Board of Directors assesses the concentration of liquidity risk to be low. The Board of Directors is confident that the Company can generate sufficient cash flows to meet its financial obligations as they come due.

34. REALATED PARTIES

During the year, the Company had the following transactions with related parties:

OPC Pharmaceutical Joint Stock Company (Parent Company)	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
		1
- Revenue from sales of finished goods and merchandise	105.541.525.463	119.477.828.760
- Returns of finished goods and merchandise	157.457	121.346.690
- Customer care expenses paid on behalf through OPC	196.980.587	880.209.438
- Truck rental	84.000.000	84.000.000
- Transfer of lease rights		399.000.000
- Purchase of raw materials and goods	51.211.340	-
OPC Binh Duong Pharmaceutical Only member Co.,Ltd	From 01st Jan till	From 01st Jan till
(company of the same parent company)	end 31st Dec 2024	end 31st Dec 2023
	VND	VND
- Purchase of goods and raw materials	403.500.000	497.000.000

Ho Chi Minh City, Viet Nam

FINANCAL STATEMENT

For the financial year ended 31st December 2024

Balances with related parties as at the date of the financial statements are as followed	31st Dec 2024	01st Jan 2024
Short-term trade receivables		
- OPC Pharmaceutical Joint Stock Company	16.956.659.585	16.419.454.616
Trade payables	31st Dec 2024	01st Jan 2024
- OPC Binh Duong Pharmaceutical Only member Co.,Ltd	46.462.500	49.350.000

Income of the Board of Directors, the Board of Management and the Supervisory Board paid during the year is as follows

	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
- Salaries, bonuses, and other benefits	2.016.381.910	2.399.379.327
35. OPERATING LEASE COMMITMENTS	From 01st Jan till end 31st Dec 2024 VND	From 01st Jan till end 31st Dec 2023 VND
Minimum operating lease expenses recognized in the income statement during the year	3.679.981.954	3.679.981.953
As at the end of the financial year, the Company has non-cancellable operating lease commitments with payment schedules as follows:	Current Period VND	Previous Period VND
- Within 1 year	551.899.214 551.899.214	1.201.734.194 1.201.734.194

Operating lease payments represent the minimum annual land rental payments the Company must make for land plots in Ho Chi Minh City, detailed as follows

Lands Rental period

- Land on 448B Nguyen Tat Thanh Street, Ward 18, District 4, Ho Chi Minh City,

- Land on 57 Nguyen Du Street, Ben Nghe Ward, District 1, Ho Chi Minh City, Vietnam

04/03/2025

31/12/2025

36. SEGMENT REPORTING

Segment information is presented by business sector or geographical area. The Company currently does not have more than one segment either by business sector or geographical area, as it operates in a single business sector, which is pharmaceuticals, and in a single geographical area, which is Vietnam. Therefore, the Company does not present segment reporting

PREPARER CUM CHIEF ACCOUNTANT

Ngo Tan Long

Ho Chi Minh City, 20th January 2025 GENNERAL DIRECTOR

Nguyen Manh Hai